Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study
Objectives - To inform health-technology assessments of new adjuvant treatments, we describe treatment patterns in patients with complete resection of stage IB-IIIA non-small cell lung cancer (NSCLC) in France, Germany, and the United Kingdom (UK). - Materials and methods - Data were collected via m...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[October 2018]
|
| In: |
Lung cancer
Year: 2018, Volume: 124, Pages: 310-316 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2018.07.042 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.lungcan.2018.07.042 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500218305038 
|
| Author Notes: | Christos Chouaid, Sarah Danson, Stefan Andreas, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Mark Price, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Sorrel Wolowacz, James A. Kaye, Ilias Kontoudis |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1664579079 | ||
| 003 | DE-627 | ||
| 005 | 20230427135428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190503s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2018.07.042 |2 doi | |
| 035 | |a (DE-627)1664579079 | ||
| 035 | |a (DE-599)KXP1664579079 | ||
| 035 | |a (OCoLC)1341212203 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chouaid, Christos |e VerfasserIn |0 (DE-588)1185223762 |0 (DE-627)1664579397 |4 aut | |
| 245 | 1 | 0 | |a Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study |c Christos Chouaid, Sarah Danson, Stefan Andreas, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Mark Price, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Sorrel Wolowacz, James A. Kaye, Ilias Kontoudis |
| 264 | 1 | |c [October 2018] | |
| 300 | |b 1 Diagramm | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.05.2019 | ||
| 520 | |a Objectives - To inform health-technology assessments of new adjuvant treatments, we describe treatment patterns in patients with complete resection of stage IB-IIIA non-small cell lung cancer (NSCLC) in France, Germany, and the United Kingdom (UK). - Materials and methods - Data were collected via medical record abstraction. Patients were aged ≥18 years with completely resected stage IB-IIIA NSCLC, diagnosed between 01 January 2009 and 31 December 2011. Median follow-up was 26 months. Adjuvant treatment patterns and clinical outcomes were summarized descriptively. - Results - Among the 831 patients studied, 239 (29%) had stage IB disease, 179 (22%) had stage IIA disease, 165 (20%) had stage IIB disease, and 248 (30%) had stage IIIA disease. Adjuvant systemic therapy was received by 402 patients (48.4%), (France, 61.8%; Germany, 51.9%; UK, 33.4%). Use of adjuvant therapy increased with increasing stage of disease. Cisplatin/vinorelbine and carboplatin/vinorelbine were the most frequently prescribed adjuvant regimens. Median disease-free survival was 48.0 months (95% confidence interval [CI] 42.3-not estimable); the 25th percentile was 13.2 months (95% CI, 11.0-15.3). 204 patients (24%) died during the follow-up period. The median overall survival was not reached, the 25th percentile was 31.2 months (95% CI 26.8-36.0 months). 272 patients (33%) had disease recurrence during the follow-up period. For 86 of those patients, the first recurrence was local or regional with no distant metastasis and 14 had further progression to metastatic disease during the follow-up time. For the other 186 patients, the first recurrence involved distant metastases. A total of 200 patients had metastatic disease at any time during study follow-up. - Conclusions - Less than half the patients with stage IB-IIIA NSCLC in this observational study received adjuvant systemic therapy. A high rate of first recurrence with distant metastatic disease was observed, emphasising the need for more effective systemic adjuvant therapies in this population. | ||
| 650 | 4 | |a Adjuvant therapy | |
| 650 | 4 | |a Burden-of-illness | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Observational study | |
| 700 | 1 | |a Hoffmann, Hans |d 1957- |e VerfasserIn |0 (DE-588)1022900455 |0 (DE-627)71732852X |0 (DE-576)366147730 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 124(2018), Seite 310-316 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study |
| 773 | 1 | 8 | |g volume:124 |g year:2018 |g pages:310-316 |g extent:7 |a Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2018.07.042 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0169500218305038 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190503 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1022900455 |a Hoffmann, Hans |m 1022900455:Hoffmann, Hans |d 910000 |d 950000 |d 950900 |e 910000PH1022900455 |e 950000PH1022900455 |e 950900PH1022900455 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 9 | ||
| 999 | |a KXP-PPN1664579079 |e 3461678074 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"7 S.","noteIll":"1 Diagramm"}],"language":["eng"],"id":{"eki":["1664579079"],"doi":["10.1016/j.lungcan.2018.07.042"]},"recId":"1664579079","title":[{"title":"Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study","title_sort":"Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study"}],"person":[{"family":"Chouaid","display":"Chouaid, Christos","roleDisplay":"VerfasserIn","given":"Christos","role":"aut"},{"display":"Hoffmann, Hans","family":"Hoffmann","roleDisplay":"VerfasserIn","given":"Hans","role":"aut"}],"note":["Gesehen am 03.05.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"[October 2018]"}],"relHost":[{"title":[{"title_sort":"Lung cancer","title":"Lung cancer","subtitle":"journal of the International Association for the Study of Lung Cancer"}],"note":["Gesehen am 20.02.20"],"part":{"year":"2018","volume":"124","extent":"7","pages":"310-316","text":"124(2018), Seite 310-316"},"type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"eki":["320649733"],"zdb":["2025812-4"],"issn":["1872-8332"]},"disp":"Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness studyLung cancer","pubHistory":["1.1985 -"],"recId":"320649733","origin":[{"dateIssuedDisp":"1985-","publisher":"Elsevier","dateIssuedKey":"1985","publisherPlace":"Amsterdam [u.a.]"}]}],"name":{"displayForm":["Christos Chouaid, Sarah Danson, Stefan Andreas, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Mark Price, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Sorrel Wolowacz, James A. Kaye, Ilias Kontoudis"]}} | ||
| SRT | |a CHOUAIDCHRADJUVANTTR2018 | ||